NASDAQ:APOP Cellect Biotechnology (APOP) Stock Price, News & Analysis → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Free APOP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$13.10▼$13.3750-Day Range$7.54▼$13.4052-Week Range$6.64▼$35.52Volume17,400 shsAverage Volume479,845 shsMarket Capitalization$12.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Cellect Biotechnology alerts: Email Address Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. About Cellect Biotechnology Stock (NASDAQ:APOP)Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.Read More Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. APOP Stock News HeadlinesMarch 1, 2024 | wsj.comKrystal Biotech Inc.June 23, 2023 | bizjournals.comRaleigh/Durham Biotech NewsApril 26, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...April 19, 2023 | seekingalpha.comSana Biotechnology Is Technically Overbought So Buy It LaterApril 19, 2023 | cnbc.comPiper Sandler says this biotech stock can outperform thanks to Alzheimer's treatmentFebruary 23, 2023 | benzinga.com$3M Bet On This Biotechnology Stock? Check Out These 3 Penny Stocks Insiders Are BuyingJanuary 30, 2023 | finance.yahoo.comGlobal Agricultural Biotechnology Market to Reach $88.9 Billion by 2030November 24, 2022 | morningstar.comWhy These Biotech Stocks Are Outperforming the MarketApril 26, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...November 16, 2022 | realmoney.thestreet.comSeeing Good Action in Biotechnology StocksSeptember 18, 2022 | fool.co.ukInvesting in Biotech: Top UK Biotech Stocks in 2022November 4, 2021 | finance.yahoo.comQuoin Pharmaceuticals Appoints Gordon Dunn as Chief Financial OfficerNovember 2, 2021 | finance.yahoo.comQuoin Pharmaceuticals Announces Signing of Exclusive License from Queensland University of Technology, AustraliaOctober 16, 2021 | apnews.comCellect Biotechnology Announces Record Date and Distribution Date for CVRs in Connection with ...October 15, 2021 | finance.yahoo.comCellect Biotechnology Announces Record Date and Distribution Date for CVRs in Connection with Strategic Merger with Quoin PharmaceuticalsOctober 14, 2021 | finanznachrichten.deCellect Biotechnology Ltd.: Cellect Biotechnology Announces Shareholder Approval of Strategic Merger with Quoin PharmaceuticalsSeptember 27, 2021 | benzinga.comWhy Cellect Biotechnology Shares Are Rising TodaySeptember 27, 2021 | finance.yahoo.comCellect Biotechnology Announces Shareholder Approval of Strategic Merger with Quoin PharmaceuticalsSeptember 3, 2021 | markets.businessinsider.comPre-market Movers: APOP, FBRX, ANY, AGIL, ADXS…September 2, 2021 | finance.yahoo.comCellect Biotechnology Announces the ApoGraft™ Bone Marrow Transplantation of First Patient in U.S.August 24, 2021 | finance.yahoo.comCellect Biotechnology Reports Second Quarter 2021 Financial and Operating ResultsAugust 13, 2021 | apnews.comThe Securities and Exchange Commission Declared Cellect Biotechnology’s Registration Statement ...August 13, 2021 | finance.yahoo.comThe Securities and Exchange Commission Declared Cellect Biotechnology’s Registration Statement Filed on Form F-4 Effective in Connection with its Previously Announced Strategic Merger with Quoin PharmaceuticalsJuly 27, 2021 | nasdaq.comCellect Biotechnology Ltd. American Depositary Shares (APOP)See More Headlines Receive APOP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellect Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2018Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & Medical Instruments Sub-IndustryN/A Current SymbolNASDAQ:APOP CUSIPN/A CIK1671502 Webwww.cellect.co Phone(729) 974-1444Fax972-9767-8750Employees2,020Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.01 Quick Ratio3.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.77 per share Price / Book2.76Miscellaneous Outstanding Shares977,000Free FloatN/AMarket Cap$12.87 million OptionableNot Optionable Beta1.87 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesShai YarkoniChief Executive Officer & DirectorAmos OferChief Operating OfficerYaron Ben-OzChief Financial OfficerKey CompetitorsMicrobot MedicalNASDAQ:MBOTBiotricityNASDAQ:BTCYNEXGELNASDAQ:NXGLPetVivoNASDAQ:PETVT2 BiosystemsNASDAQ:TTOOView All Competitors APOP Stock Analysis - Frequently Asked Questions How were Cellect Biotechnology's earnings last quarter? Cellect Biotechnology Ltd. (NASDAQ:APOP) released its earnings results on Tuesday, November, 13th. The company reported ($0.58) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by $0.02. When did Cellect Biotechnology's stock split? Shares of Cellect Biotechnology split before market open on Tuesday, October 26th 2021. The 2-1 split was announced on Tuesday, October 26th 2021. The newly issued shares were issued to shareholders after the closing bell on Tuesday, October 26th 2021. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. What other stocks do shareholders of Cellect Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cellect Biotechnology investors own include Elbit Systems (ESLT), Gilead Sciences (GILD), Pluristem Therapeutics (PSTI), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Acasti Pharma (ACST), Allergan (AGN), Novavax (NVAX) and RedHill Biopharma (RDHL). This page (NASDAQ:APOP) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellect Biotechnology Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
